Erbitux

(Cetuximab)

ApprovedMonoclonal antibody

Cetuximab is used to treat certain types of cancer, including colorectal cancer and head and neck cancer, by blocking a protein that helps cancer cells grow.[2] Erbitux is currently approved and in use across 74 indications[4].[1]

Erbitux is one of 892 small molecule programs targeting Advanced Solid Tumors. It is currently in Approved.

Indications

838

Total Trials

Active Trials

891

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Advanced Solid TumorsCompleted

Pancreatic Ductal AdenocarcinomaActive, not recruiting

TreatmentRecruiting

Solid TumorsRecruiting

BevacizumabTerminated

Patients With Solid TumorsCompleted

MetastaticTerminated

Patients With Advanced Solid TumorsActive, not recruiting

Head and Neck Squamous Cell CancerRecruiting

Locally Advanced Head and Neck CancerActive, not recruiting

Advanced Solid TumorsPhase 2

Completed

Pancreatic Ductal AdenocarcinomaPhase 1

Active, not recruiting

TreatmentPhase 2

Recruiting

Solid TumorsPhase 2

Recruiting

BevacizumabPhase 2

Terminated

Patients With Solid TumorsPhase 1

Completed

MetastaticPhase 2

Terminated

Patients With Advanced Solid TumorsPhase 2

Active, not recruiting

Head and Neck Squamous Cell CancerPhase 2

Recruiting

Locally Advanced Head and Neck CancerPhase 3

Active, not recruiting

Showing 10 of 74 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Erbitux

IImclone

Approved

41 2

Verzenio

Eli Lilly

Phase 3

6 3

Leqembi

Eisai

Phase 3

1 4

Faslodex

FFresenius Kabi USA, LLC

Phase 3

4 5

Remeron

OOrganon and Co

Preclinical

1 6

Treatment

GSK

Preclinical

1 7

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Patients With Advanced Solid Tumors

NCT05358249

Q2 2027

Phase 1/2Recruiting

KRAS G12C

NCT04956640

Phase 1Recruiting

Pembrolizumab

NCT06912087

Q4 2027

Phase 2Recruiting

Colorectal Cancer

NCT06540326

Phase 1/2Active, not recruiting

Metastatic Colorectal Cancer

NCT04017650

Phase 3Recruiting

Metastatic Colorectal Cancer

NCT06226857

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer29 trials

ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer

Completed·—·Phase 1·NCT00436072·46 enrolled

Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer

Unknown status·CCinnagen·Phase 3·NCT03391934·234 enrolled

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1/2·NCT01075048·131 enrolled

Show 26 more trials

Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA

Recruiting·FFudan University·Phase 2·NCT06440902·1,100 enrolled

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04017650·38 enrolled

A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

Unknown status·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 1·NCT03356158·21 enrolled

The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment

Unknown status·NNational Health Research Institutes, Taiwan··NCT03401957·120 enrolled

MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Completed· Menarini logo

Menarini·Phase 1/2·NCT04495621·29 enrolled

Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Unknown status·VVelindre NHS Trust·Phase 3·NCT00182715·2,421 enrolled

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

Completed· Roche logo

Roche·Phase 2·NCT02291289·1,044 enrolled

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Recruiting·—·Phase 3·NCT06226857·355 enrolled

Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 2·NCT04561336·77 enrolled

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Completed·SSwedish Medical Center·Phase 1·NCT01294826·20 enrolled

Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab

Completed·UUNICANCER·Phase 2·NCT01442649·133 enrolled

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

Withdrawn·NNSABP Foundation Inc·Phase 1/2·NCT01960023

Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer

Completed·TTechnische Universität Dresden·Phase 1/2·NCT00422773·21 enrolled

Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Completed·SSun Yat-sen University·Phase 1/2·NCT04790448·37 enrolled

Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01198535·60 enrolled

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 1·NCT05954871·10 enrolled

XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer

Unknown status·GGrupo de Investigacao do Cancro Digestivo·Phase 2·NCT00215722·45 enrolled

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2·NCT00556413·42 enrolled

Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer

Completed·IInstitut Cancerologie de l'Ouest·Phase 2·NCT00559741·80 enrolled

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT01326000·169 enrolled

A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01228734·553 enrolled

A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01152437·94 enrolled

Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

Unknown status·LLeiden University Medical Center·Phase 2·NCT01190462·51 enrolled

FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor

Completed·PPer Pfeiffer·Phase 2·NCT00660582·152 enrolled

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

Unknown status· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 2·NCT04984369·50 enrolled

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Unknown status·WWest China Hospital·Phase 1·NCT05019534·12 enrolled

Colorectal Cancer24 trials

Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement

Terminated·WWashington University School of Medicine·Phase 2·NCT00537823·9 enrolled

Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

Withdrawn·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00571740

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Completed·RRoswell Park Cancer Institute·Phase 1/2·NCT02713373·45 enrolled

Show 21 more trials

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery

Unknown status·—·Phase 2·NCT00513266·35 enrolled

Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer

Completed·MMedical Research Council·Phase 2/3·NCT00975897·3,240 enrolled

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Unknown status·PPD Dr. med. Volker Heinemann·Phase 3·NCT00433927·568 enrolled

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Completed·SSWOG Cancer Research Network·Phase 2·NCT03365882·240 enrolled

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06490913·33 enrolled

Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer

Terminated·IInstitut Bergonié·Phase 2·NCT00766142·18 enrolled

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06540326·100 enrolled

A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00551213·67 enrolled

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

Not yet recruiting·LLiaoning Cancer Hospital & Institute·Phase 2·NCT05720559·100 enrolled

SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

Terminated·MMassachusetts General Hospital·Phase 1/2·NCT00361244·6 enrolled

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00326495·51 enrolled

Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00061815·102 enrolled

Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer

Completed·—·Phase 2·NCT00689624·30 enrolled

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03563157·2 enrolled

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00055419·744 enrolled

A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

Terminated·SSOTIO Biotech AG·Phase 2·NCT05619172·16 enrolled

Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.

Completed·RRegione Lombardia·Phase 2·NCT01068132·54 enrolled

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00063141·1,302 enrolled

A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 2·NCT01776307·200 enrolled

Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer

Terminated· EMD Serono logo

EMD Serono·Phase 1·NCT00719199·21 enrolled

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01032291·51 enrolled

Squamous Cell Carcinoma16 trials

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Completed·WWashington University School of Medicine·Phase 1/2·NCT02101034·96 enrolled

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Withdrawn· Incyte logo

Incyte·Phase 3·NCT03342352

A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01177956·73 enrolled

Show 13 more trials

Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma

Active, not recruiting·MMahidol University·Phase 1/2·NCT03024489·27 enrolled

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Recruiting·GGrupo Español de Tratamiento de Tumores de Cabeza y Cuello·Phase 2·NCT06856213·65 enrolled

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

Completed· Roche logo

Roche·Phase 2·NCT01577173·122 enrolled

Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Unknown status·TTrans Tasman Radiation Oncology Group·Phase 3·NCT01855451·189 enrolled

Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT00705016·184 enrolled

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03386838

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed·NNanoCarrier Co., Ltd.·Phase 1/2·NCT03109158·1 enrolled

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Terminated·—·Phase 2·NCT01488318·21 enrolled

Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Terminated·UUniversity of Tennessee Cancer Institute·Phase 1/2·NCT01015664·11 enrolled

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed·IInnate Pharma·Phase 1/2·NCT02643550·143 enrolled

An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Terminated· Merck & Co. logo

Merck & Co.··NCT01142869·133 enrolled

Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

Recruiting·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 2·NCT06640725·70 enrolled

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00617734·97 enrolled

Head and Neck Cancer13 trials

Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer

Terminated·BBoneca Corporation·Phase 1/2·NCT00927147·17 enrolled

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

Terminated·GGeorgetown University·N/A·NCT01790516·2 enrolled

Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00646659·47 enrolled

Show 10 more trials

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03349710·74 enrolled

Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer

Terminated·RRutgers, The State University of New Jersey·N/A·NCT02177838·8 enrolled

Cetuximab in Head and Neck Cancer Patients

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT03769311·15 enrolled

Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer

Withdrawn·GGeorgetown University·Phase 2·NCT00881114

CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer

Completed·GGlycotope GmbH·Phase 2·NCT02052960·240 enrolled

Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT00671437·42 enrolled

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Terminated·UUniversity of Kansas Medical Center·Phase 2·NCT00591149·16 enrolled

Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer

Completed·UUniversity of Pittsburgh·Phase 1·NCT00291707·40 enrolled

Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

Completed·UUniversity of Pittsburgh·Phase 2·NCT00226239·39 enrolled

Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00089297·74 enrolled

Non-Small Cell Lung Cancer10 trials

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

Completed·UUniversity of California, Davis·Phase 1/2·NCT00408499·64 enrolled

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00986674·140 enrolled

Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)

Completed·SSwiss Cancer Institute·Phase 2·NCT01059188·69 enrolled

Show 7 more trials

Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00097227·165 enrolled

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00533949·544 enrolled

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers

Recruiting·HHummingbird Bioscience·Phase 1/2·NCT05910827·98 enrolled

Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01109524·72 enrolled

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01090011·171 enrolled

Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00124618·58 enrolled

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

Completed·HHiberCell, Inc.·Phase 2·NCT00874848·90 enrolled

70 more indications

Head and Neck Squamous Cell Carcinoma5 trials

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 3·NCT06647563·355 enrolled

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated· Novartis logo

Novartis·Phase 1/2·NCT01602315·179 enrolled

A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma

Completed· Roche logo

Roche·Phase 1·NCT01046266·62 enrolled

Show 2 more trials

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Completed·JJames J Lee·Phase 1·NCT02277197·14 enrolled

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Not yet recruiting·VVanderbilt-Ingram Cancer Center·Phase 1·NCT07217028·60 enrolled

Esophageal Cancer4 trials

Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery

Completed·FFederation Francophone de Cancerologie Digestive·Phase 1/2·NCT00544362·33 enrolled

S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00109850·22 enrolled

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00381706·245 enrolled

Show 1 more trial

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

Terminated·EEastern Cooperative Oncology Group·Phase 2·NCT00551759·22 enrolled

Head and Neck Squamous Cell Cancer4 trials

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07063212·40 enrolled

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00661427·61 enrolled

Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer

Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 2·NCT01326923·7 enrolled

Show 1 more trial

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03667482·20 enrolled

Pancreatic Cancer4 trials

Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 1/2·NCT00923299·33 enrolled

Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery

Terminated·EEben Rosenthal·Phase 2·NCT02736578·8 enrolled

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Completed·RR-Pharm·Phase 2·NCT00383149·58 enrolled

Show 1 more trial

Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00042939·94 enrolled

Advanced Solid Tumors3 trials

Study in Advanced Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01099358·47 enrolled

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Completed·FFate Therapeutics·Phase 1·NCT03319459·44 enrolled

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Completed· GSK logo

GSK·Phase 1/2·NCT03693612·26 enrolled

Metastatic Head and Neck Cancer3 trials

Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab

Terminated·UUniversity of California, Irvine·Phase 2·NCT00319839·10 enrolled

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01256385·86 enrolled

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02252042·495 enrolled

Bevacizumab3 trials

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00941499·140 enrolled

A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab

Unknown status·JJapan Clinical Cancer Research Organization·Phase 2·NCT02515734·360 enrolled

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

Recruiting·SSun Yat-sen University·Phase 1/2·NCT07012954·64 enrolled

Advanced Head and Neck Cancer3 trials

A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab

Completed·UUniversity of Zurich·Phase 2·NCT01435252·68 enrolled

A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer

Completed·EEmory University·Phase 1/2·NCT01283334·20 enrolled

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

Completed·SState University of New York - Upstate Medical University·Phase 1/2·NCT00660218·53 enrolled

Locally Advanced Head and Neck Cancer3 trials

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer

Completed·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT00851877·37 enrolled

Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer

Terminated·AAzienda USL 4 Prato·Phase 2·NCT01216020·70 enrolled

Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer

Completed·UUniversity of Pittsburgh·Phase 2·NCT00703976·80 enrolled

Gastric Cancer3 trials

Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer

Terminated·DDr Anna Dorothea Wagner·Phase 1/2·NCT01611506·1 enrolled

Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01388790·40 enrolled

Study of Cetuximab to Treat Gastric Cancer

Completed·FFudan University·Phase 2·NCT00699881·61 enrolled

Solid Tumors2 trials

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Recruiting·VVerastem, Inc.·Phase 1/2·NCT07020221·295 enrolled

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT02671435·383 enrolled

Colorectal Carcinoma2 trials

Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma

Completed·HHiberCell, Inc.·Phase 1/2·NCT00545545·32 enrolled

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02563002·307 enrolled

Radiation Therapy2 trials

Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer

Completed·EECOG-ACRIN Cancer Research Group·Phase 2·NCT00316888·63 enrolled

Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT00383695·164 enrolled

Breast Cancer2 trials

Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer

Unknown status·MMedical University of Vienna·Phase 1·NCT00367250·32 enrolled

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00275041·21 enrolled

Recurrent Head and Neck Cancer2 trials

Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397

Completed·EEastern Cooperative Oncology Group··NCT01466244·42 enrolled

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003809

Patients With Advanced Solid Tumors2 trials

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Active, not recruiting· Novartis logo

Novartis·Phase 1/2·NCT05358249·74 enrolled

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Completed·JJacobio Pharmaceuticals Co., Ltd.·Phase 1/2·NCT05002270·29 enrolled

Radiotherapy2 trials

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Recruiting·CChristopher Wilke·Phase 2·NCT02128906·120 enrolled

Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Completed·CCentre Oscar Lambret··NCT01647555·57 enrolled

Gastrointestinal2 trials

Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab

Completed·—·Phase 1·NCT02845999·9 enrolled

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Completed·EErasca, Inc.·Phase 1/2·NCT05039177·101 enrolled

Prostate Cancer2 trials

Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

Terminated·TThe Methodist Hospital Research Institute·Phase 2·NCT00448097·7 enrolled

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

Completed·UUS Oncology Research·Phase 2·NCT00661492·115 enrolled

Head Neck Cancer2 trials

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01581970·7 enrolled

Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer

Unknown status·—·Phase 1/2·NCT03051906·69 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT02123381·100 enrolled

Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma

Completed·SShandong Cancer Hospital and Institute·Phase 2·NCT00815308·55 enrolled

Advanced Solid Malignancies2 trials

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT07223047·252 enrolled

Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

Completed·UUniversity of Pittsburgh·Phase 1·NCT00388427·31 enrolled

Liver Metastases1 trial

Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

Completed·EEPS Corporation·N/A·NCT01834014·110 enrolled

Neoadjuvant1 trial

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02124850·18 enrolled

Locally Advanced1 trial

Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC

Completed·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 2·NCT02707588·133 enrolled

Preoperative1 trial

Preoperative Treatment With Cetuximab and/or IMC-A12

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00957853·16 enrolled

KRAS G12C1 trial

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT04956640·540 enrolled

Growth1 trial

A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

Completed· Roche logo

Roche·Phase 1·NCT01482377·145 enrolled

Advanced Urothelial Cancer1 trial

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Completed·FFox Chase Cancer Center·Phase 2·NCT00350025·41 enrolled

Lung Cancer1 trial

Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer

Completed·—·Phase 2·NCT00165334·53 enrolled

Cervical Cancer1 trial

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer

Completed·IInstitut Curie·Phase 2·NCT00957411·76 enrolled

Parenteral Nutrition1 trial

Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck

Terminated·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 3·NCT02236936·8 enrolled

Metastatic Prostate Cancer1 trial

Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer

Completed·SSwiss Cancer Institute·Phase 2·NCT00728663·35 enrolled

Chemotherapy1 trial

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03186326·132 enrolled

Adenocarcinoma1 trial

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00077233·238 enrolled

Squamous Cell Cancer1 trial

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Completed·YYale University·Phase 2·NCT02979977·50 enrolled

Head and Neck1 trial

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

Terminated· Sanofi logo

Sanofi·Phase 2·NCT05061420·59 enrolled

Intensity-modulated Radiation Therapy1 trial

Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02282371·16 enrolled

Recurrent or Metastatic1 trial

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01087970·69 enrolled

BRAF1 trial

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).

Unknown status·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT02296203·27 enrolled

HNSCC1 trial

Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06935188·98 enrolled

Hematologic Cancer1 trial

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03783403·206 enrolled

Carboplatin1 trial

Paclitaxel/Carboplatin With or Without Cetuximab in CUP

Unknown status·HHeidelberg University·Phase 2·NCT00894569·150 enrolled

Head and Neck Carcinoma1 trial

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02105636·361 enrolled

Overall Survival1 trial

Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma

Terminated·BBart Neyns·Phase 2·NCT01044225·12 enrolled

Cancer of the Pancreas1 trial

Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas

Withdrawn·UUniversity of Alabama at Birmingham·Phase 2·NCT00005591

Maintenance Treatment1 trial

Cetuximab Monotherapy Maintenance Treatment in mCRC

Unknown status·RRuijin Hospital·Phase 2/3·NCT02978313·500 enrolled

Hypofractionated Radiotherapy1 trial

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT06928584·221 enrolled

Advanced Cancers1 trial

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Completed·MMerrimack Pharmaceuticals·Phase 1·NCT01451632·48 enrolled

Adenoid Cystic Carcinoma1 trial

Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy

Unknown status·HHeidelberg University·Phase 1/2·NCT01192087·49 enrolled

Unknown status·TTrial Form Support S.L.·Phase 2·NCT00251381·90 enrolled

Acne1 trial

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab

Completed·RRambam Health Care Campus··NCT01382407·100 enrolled

Pembrolizumab1 trial

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Recruiting·UUniversity of Chicago·Phase 1·NCT06912087·36 enrolled

Hepatocellular Carcinoma1 trial

Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT00142428·30 enrolled

Surgical1 trial

Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures

Terminated·EEben Rosenthal·Phase 1·NCT01987375·1 enrolled

Glioblastoma1 trial

Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas

Completed·RRigshospitalet, Denmark·Phase 2·NCT00463073·32 enrolled

ESS1 trial

QUantitative Assessment of Swallowing After Radiation (QUASAR)

Unknown status·—··NCT04359199·42 enrolled

Small Cell Lung Cancer1 trial

Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00842712·232 enrolled

Combination Therapy1 trial

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Completed·CC4 Therapeutics, Inc.·Phase 1·NCT05668585·89 enrolled

Tics1 trial

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

Completed· Bayer logo

Bayer·Phase 1·NCT01973868·42 enrolled

Advanced or Metastatic Solid Tumors1 trial

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00908024·54 enrolled

Metastasis1 trial

FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis

Recruiting·TTongji Hospital·Phase 2·NCT06988852·300 enrolled

Advanced Solid Tumours1 trial

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02020577·58 enrolled

Phase 11 trial

Phase 1 and 2 Study of PX-866 and Cetuximab

Completed·CCascadian Therapeutics Inc.·Phase 1/2·NCT01252628·178 enrolled

Malignant Pleural Mesothelioma1 trial

A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

Completed·UUniversity Hospital, Ghent·Phase 2·NCT00996567·22 enrolled

Microsatellite Stable1 trial

Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer

Unknown status·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT03608046·59 enrolled

Anal Carcinoma1 trial

Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)

Unknown status·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT03944252·54 enrolled

Unspecified2 trials

A Study of Mitomycin C, Irinotecan, and Cetuximab

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00271011·13 enrolled

c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI

Unknown status·FFudan University·Phase 2·NCT04833036·120 enrolled

Regulatory

FDA Approval Timeline[5]

Feb 12, 2004

ERBITUX

BLA BLA125084

Jun 18, 2004

ERBITUX

NDA BLA125084

Sep 1, 2005

ERBITUX

NDA BLA125084

Mar 1, 2006

ERBITUX

NDA BLA125084

Mar 1, 2006

ERBITUX

NDA BLA125084

Oct 2, 2007

ERBITUX

NDA BLA125084

Nov 20, 2007

ERBITUX

NDA BLA125084

Sep 12, 2008

ERBITUX

NDA BLA125084

Jul 17, 2009

ERBITUX

NDA BLA125084

Jul 17, 2009

ERBITUX

NDA BLA125084

Jul 8, 2010

ERBITUX

NDA BLA125084

Mar 24, 2011

ERBITUX

NDA BLA125084

Nov 7, 2011

ERBITUX

NDA BLA125084

Jan 19, 2012

ERBITUX

NDA BLA125084

Jan 24, 2012

ERBITUX

NDA BLA125084

Jul 6, 2012

ERBITUX

NDA BLA125084

Mar 4, 2013

ERBITUX

NDA BLA125084

Mar 11, 2015

ERBITUX

NDA BLA125084

Apr 10, 2015

ERBITUX

NDA BLA125084

Oct 11, 2016

ERBITUX

NDA BLA125084

May 4, 2018

ERBITUX

NDA BLA125084

Jun 5, 2018

ERBITUX

NDA BLA125084

Apr 23, 2019

ERBITUX

NDA BLA125084

Nov 10, 2020

ERBITUX

NDA BLA125084

Apr 6, 2021

ERBITUX

NDA BLA125084

Apr 6, 2021

ERBITUX

NDA BLA125084

Sep 24, 2021

ERBITUX

NDA BLA125084

Sources

References

[1]
ClinicalTrials.gov — 838 trial records for Cetuximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Erbitux drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Cetuximab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Cetuximab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA BLA125084). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Imclone company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Epidermal Growth Factor Receptor Erbb1 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: IImclone

Erbitux

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Trials by Indication[1]

Metastatic Colorectal Cancer29 trials

Colorectal Cancer24 trials

Squamous Cell Carcinoma16 trials

Head and Neck Cancer13 trials

Non-Small Cell Lung Cancer10 trials

Head and Neck Squamous Cell Carcinoma5 trials

Esophageal Cancer4 trials

Head and Neck Squamous Cell Cancer4 trials

Pancreatic Cancer4 trials

Advanced Solid Tumors3 trials

Metastatic Head and Neck Cancer3 trials

Bevacizumab3 trials

Advanced Head and Neck Cancer3 trials

Locally Advanced Head and Neck Cancer3 trials

Gastric Cancer3 trials

Solid Tumors2 trials

Colorectal Carcinoma2 trials

Radiation Therapy2 trials

Breast Cancer2 trials

Recurrent Head and Neck Cancer2 trials

Patients With Advanced Solid Tumors2 trials

Radiotherapy2 trials

Gastrointestinal2 trials

Prostate Cancer2 trials

Head Neck Cancer2 trials

Esophageal Squamous Cell Carcinoma2 trials

Advanced Solid Malignancies2 trials

Liver Metastases1 trial

Neoadjuvant1 trial

Locally Advanced1 trial

Preoperative1 trial

KRAS G12C1 trial

Growth1 trial

Advanced Urothelial Cancer1 trial

Lung Cancer1 trial

Cervical Cancer1 trial

Parenteral Nutrition1 trial

Metastatic Prostate Cancer1 trial

Chemotherapy1 trial

Adenocarcinoma1 trial

Squamous Cell Cancer1 trial

Head and Neck1 trial

Intensity-modulated Radiation Therapy1 trial

Recurrent or Metastatic1 trial

BRAF1 trial

HNSCC1 trial

Hematologic Cancer1 trial

Carboplatin1 trial

Head and Neck Carcinoma1 trial

Overall Survival1 trial

Cancer of the Pancreas1 trial

Maintenance Treatment1 trial

Hypofractionated Radiotherapy1 trial

Advanced Cancers1 trial

Adenoid Cystic Carcinoma1 trial

Cancer1 trial

Refractory Solid Tumors1 trial

Oropharynx Squamous Cell Carcinoma1 trial

Acne1 trial

Pembrolizumab1 trial

Hepatocellular Carcinoma1 trial

Surgical1 trial

Glioblastoma1 trial

ESS1 trial

Small Cell Lung Cancer1 trial

Combination Therapy1 trial

Tics1 trial

Advanced or Metastatic Solid Tumors1 trial

Metastasis1 trial

Advanced Solid Tumours1 trial

Phase 11 trial

Malignant Pleural Mesothelioma1 trial